Sunovion Pharmaceuticals Inc.
84 Waterford Drive
Marlborough
Massachusetts
01752
United States
Tel: 508-481-6700
Website: http://www.sunovion.com/
About Sunovion Pharmaceuticals Inc.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
340 articles about Sunovion Pharmaceuticals Inc.
-
Sepracor, Inc. Reports 2007 Fourth Quarter and Full-Year Results, Forecasts Stronger Revenue Growth for 2008
2/29/2008
-
Sepracor, Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2007 Operating Results
2/26/2008
-
Sepracor, Inc. Announces Internal Review of Government Price Reporting Matters
1/29/2008
-
Sepracor, Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2007 Operating Results
1/23/2008
-
Sepracor, Inc.'s Executive Chairman to Retire by May 13
1/4/2008
-
Sepracor, Inc. Announces Completion of SEC Investigation
11/27/2007
-
SEC Ends Probe of Sepracor, Inc.; No Action Recommended
11/27/2007
-
Sepracor, Inc. Announces Appointment of Lisa Ricciardi as Board Member
11/13/2007
-
Sepracor, Inc. Announces the Establishment of a Unique Product-Specific Billing Code (or J-Code) for BROVANA(R)
11/5/2007
-
Sepracor, Inc.: BROVANA™ Inhalation Solution Study Data Presented at American College of Chest Physicians Annual Conference
10/25/2007
-
Sepracor, Inc. Sets Conference Call and Webcast for Third Quarter 2007 Operating Results
10/17/2007
-
Sepracor, Inc. Announces Senior Management Appointments as Part of Commercial Re-Organization
10/15/2007
-
Dey, L.P. Trial Date Set for Patent Infringement Suit Against Sepracor, Inc.'s Brovana(TM)
9/21/2007
-
Sepracor, Inc. Signs Sleep Drug Partnership with GlaxoSmithKline; Sepracor to Receive Up to $155 Million
9/11/2007
-
Sepracor, Inc. Submits LUNIVIA® (LUNESTA® in U.S.) Marketing Authorization Application (MAA) for Europe
7/27/2007
-
Sepracor, Inc. Announces Second Quarter 2007 Results and Significant Milestone Events
7/27/2007
-
Sepracor, Inc. Sets Conference Call and Webcast for Second Quarter 2007 Operating Results
7/17/2007
-
Sepracor, Inc. Issues Statement Regarding CMS Medicare Part B Reimbursement Change for XOPENEX(R) Inhalation Solution
6/18/2007
-
Sepracor, Inc. (Jobs) Announces Adrian Adams Assumes President and Chief Executive Officer Position
5/15/2007
-
Sepracor, Inc. Announces First Quarter 2007 Results
4/24/2007